{'fraction_non_alphanumeric': 0.050204918032786885, 'fraction_numerical': 0.018442622950819672, 'mean_word_length': 5.64625850340136, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 1, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Interaction of the new gestagen compound 17alpha-acetoxy-3beta-butanoyloxy-6-methylpregna-4,6-dien-20-one with human blood proteins and calf embryo serum].

Molecular mechanisms of sex hormones (progesterone, medroxyprogesterone acetate (MPA), and new synthetic gestagen 17alpha-acetoxy-3beta-butanoyloxy-6-methylpregna-4,6-dien-20-on (ABMP) with human serum albumin, globulins, and calf embryo serum were studied. The binding of ABMP to albumin and progesterone-binding proteins were investigated using spectroscopic techniques (with the use of 1-anilino-8-naphthalenesulfonate as fluorescent probe) and radiolabeled progesterone, (either progesteron or MPA as comparative progestines). There is no difference between the non-specific binding of ABMP, progesterone, and MPA, but the ABMP binding is much smaller as compared to the binding of progestines, so that the new progestine ABMP will produce a more effective action on the target tissue than comparative progestines.